Apellis Pharmaceuticals, Inc. Overview
Pro stress-test →Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. The company has ushered in the first new class of complement medicine in 15 years with two C3-targeting medicines approved to treat four serious diseases, including the first-ever therapy for geographic atrophy (a leading cause of blindness) and the first treatment for patients 12+ with C3G or primary IC-MPGN.
Strategic Profile
Pro stress-test →Apellis focuses on complement system inhibition at the C3 level (the central protein in the complement cascade) for rare disease treatment. The company has achieved GAAP profitability after years of R&D spending, with EPS rising 116% in the last year—an important inflection point for a growth-stage biotech.
Competitive Landscape
Pro stress-test →Apellis has 91 competitors including various biopharmaceutical firms targeting complement pathways and rare diseases. Primary competition in geographic atrophy treatment includes other complement inhibitors and intravitreal therapies. In kidney disease, Apellis faces competition from other rare disease therapies but benefits from its approved C3-targeting mechanism of action.
Industry Context
Apellis Pharmaceuticals, Inc. operates in Biopharmaceuticals - Rare Diseases & Complement Therapeutics.
Key facts
Founded: 2009 · Headquarters: Waltham, Massachusetts, US · Revenue: $1.0B · Market cap: $2.68B